PMID- 23174047
OWN - NLM
STAT- MEDLINE
DCOM- 20130528
LR  - 20151119
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 11
IP  - 4
DP  - 2012 Dec
TI  - The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 
      0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, 
      single-blind, split-face study.
PG  - 251-60
LID - 10.1111/jocd.12013 [doi]
AB  - BACKGROUND: Topical combination therapy, such as that with fixed-dose 
      clindamycin/benzoyl peroxide (BPO) or adapalene/BPO, is the recommended 
      first-line approach for the treatment of facial acne. AIMS: To compare the 
      tolerability of clindamycin 1%/BPO 5% gel vs. adapalene 0.1% BPO 2.5% gel for the 
      first 2 weeks of treatment in patients with facial acne. PATIENTS/METHODS: Using 
      a randomized, single-blind, split-face method, 48 patients with acne received 
      both clindamycin/BPO and adapalene/BPO once daily for 2 weeks. The primary 
      endpoint was investigator-assessed tolerability. Treatment efficacy, 
      patient-assessed tolerability and satisfaction, and safety were also 
      investigated. RESULTS: Forty-five patients completed treatment. 
      Investigator-rated scores for erythema, dryness, and peeling were significantly 
      higher with adapalene/BPO than clindamycin/BPO. Patients rated clindamycin/BPO as 
      significantly more tolerable than adapalene/BPO for redness, dryness, burning, 
      itching, and scaling. Investigator Static Global Assessment scores and lesion 
      counts improved with both products, with no significant difference between 
      treatments. Patients' Global Change Assessment showed a statistically significant 
      difference in favor of clindamycin/BPO at week 1, but not week 2. Overall, >80% 
      of patients were "satisfied" or "very satisfied" with treatment at week 2, but 
      63% of patients stated that they preferred clindamycin/BPO. Both products were 
      well tolerated, with no serious adverse events (AEs), but a post hoc analysis 
      indicated that treatment-related AEs, including irritation, dryness and erythema, 
      were significantly less common with clindamycin/BPO. CONCLUSIONS: Clindamycin/BPO 
      had a better tolerability profile than adapalene/BPO during 2 weeks of split-face 
      treatment. Treatment satisfaction was highest with clindamycin/BPO.
CI  - (c) 2012 Wiley Periodicals, Inc.
FAU - Gonzalez, Pablo
AU  - Gonzalez P
AD  - Buenos Aires Skin, Buenos Aires, Argentina. gonzalezp@gmail.com
FAU - Vila, Ricardo
AU  - Vila R
FAU - Cirigliano, Marcela
AU  - Cirigliano M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Gels)
RN  - 0 (Naphthalenes)
RN  - 1L4806J2QF (Adapalene)
RN  - 3U02EL437C (Clindamycin)
RN  - W9WZN9A0GM (Benzoyl Peroxide)
SB  - IM
MH  - Acne Vulgaris/*drug therapy
MH  - Adapalene
MH  - Adult
MH  - Anti-Bacterial Agents/*adverse effects/therapeutic use
MH  - Benzoyl Peroxide/*adverse effects/therapeutic use
MH  - Clindamycin/*adverse effects/therapeutic use
MH  - Dermatologic Agents/*adverse effects/therapeutic use
MH  - Drug Combinations
MH  - Erythema/chemically induced
MH  - Facial Dermatoses/*drug therapy
MH  - Female
MH  - Gels
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naphthalenes/*adverse effects/therapeutic use
MH  - Pain/chemically induced
MH  - Patient Preference
MH  - Pruritus/chemically induced
MH  - Severity of Illness Index
MH  - Single-Blind Method
MH  - Statistics, Nonparametric
MH  - Young Adult
EDAT- 2012/11/24 06:00
MHDA- 2013/05/29 06:00
CRDT- 2012/11/24 06:00
PHST- 2012/08/08 00:00 [accepted]
PHST- 2012/11/24 06:00 [entrez]
PHST- 2012/11/24 06:00 [pubmed]
PHST- 2013/05/29 06:00 [medline]
AID - 10.1111/jocd.12013 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2012 Dec;11(4):251-60. doi: 10.1111/jocd.12013.